Oxford Biomedica enters into deal to broaden viral vector offerings

Oxford Biomedica

Cell and gene therapy specialist Oxford Biomedica has announced its intention to form a viral vector manufacturing business with US-based genetic medicines company Homology Medicines.

The British firm said it would acquire an 80 per cent stake in the new firm, valued at about £175 million.

It said the venture would establish a presence in the US and offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in adeno-associated virus cell and gene therapies.

Oxford Biomedica Solutions’ AAV Manufacturing and Innovation Business is to be led by Tim Kelly as Chief Executive Officer and Chair of its Board of Directors.

Dr Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented: “Accessing Homology Medicines’ unique AAV capabilities is a major advancement in Oxford Biomedica’s goal to become an innovative global viral vector leader that provides solutions to Cell and Gene Therapy Biotech and Biopharma companies for their process development and manufacturing needs across key viral vectors.

“Oxford Biomedica is in a strong position to enable our customers to bring their new medicines to many more patients and change their lives.”

Arthur Tzianabos, President and Chief Executive Officer of Homology Medicines, said: “We chose Oxford Biomedica for its leadership in viral-based manufacturing and prestigious global client base, and we believe that Oxford Biomedica Solutions will build upon the strengths of both companies.

Oxford Biomedica also announced that Dr Roch Doliveux will assume the role of interim CEO of Oxford Biomedica, as well as Chair of the Group’s Board, and that John Dawson will retire from the Group as CEO with immediate effect, whilst remaining a Board Director and Advisor to the Group. A search for a permanent CEO successor is underway.

John Dawson added: “I am excited that this will be my final deal as CEO of the Group. This transaction not only brings proven, scalable, high-quality AAV manufacturing capabilities to Oxford Biomedica, which was in line with our strategy, but also expands Oxford Biomedica’s presence into the US and brings us a dedicated team in close geographic proximity to other leading gene therapy companies in Boston and more widely across the US.”